Mission Statement

Our company develops innovative microbiome products that are impactful and beneficial for the health of the planet. Our aim is to eliminate disease, reduce antibiotic resistance, and contribute to overall understanding of how the microbiome can promote host health and well-being.

Resilient Biotics is developing breakthrough live biotherapeutics to combat complex respiratory infections.

Using proprietary discovery analytics, we identify and design novel microbiome products that prevent disease-causing pathogens from taking hold in the respiratory tract. Our approach provides a new solution to help reduce dependency on antibiotics, and slow the spread of antibiotic-resistant microorganisms.

The company is building a portfolio of novel microbiome products to address major respiratory diseases in both human and animal health. Resilient is headquartered in the USA and is venture-backed by both institutional and strategic investors.